Price
No data yet.
Social Signal Score
Analyst Ratings
13 analystsRevenue
$0.00-100.00%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Malte Peters
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 137
- Beta
- 1.12
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 45.87
Financials
Revenue
$0.00-100.0%Net Income
$-55.34MEBITDA
$-55.34MFree Cash Flow
$-38.87MEPS (diluted)
$-0.37Shares Outstanding (diluted)
149.88M+71.3%Operating Expenses
$59.78MCash & Debt
$1.01BRevenue by Segment (annual)
$62.38MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $62.38M | $-101.59M | $-0.87 |
| 2024 | $42.07M | $-130.30M | $-1.19 |
| 2023 | $36.53M | $-101.74M | $-1.08 |
| 2022 | $24.86M | $-108.18M | $-1.23 |
| 2021 | $37.04M | $-58.23M | $-0.94 |
| 2020 | $7.66M | $-51.97M | $-1.62 |
| 2019 | $24.65M | $-14.10M | $-1.57 |
Valuation
TNGXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+25.00%Social Signal Score
Mentions (3)
- Newszacks.com·25d ago·Neutral
Why Is Tango Therapeutics (TNGX) Down 6.2% Since Last Earnings Report? Tango Therapeutics (TNGX) reported earnings 30 days ago. What's next for the stock?
View source ↗ - Newsseekingalpha.com·51d ago·Positive
…d the opportunity, although its final design, timing, and regulatory path remain unsettled. Additional combination, lung-cancer, and CNS readouts should show whether TNGX is building a broader PRMT5 franchise or relying too heavily on one early dataset.
View source ↗ - Newszacks.com·54d ago·Negative
TNGX Stock Dips 5% as Q2 Earnings Miss Estimates on Higher Expenses Tango Therapeutics stock falls 5% on a wider-than-expected Q2 loss, reflecting higher operating expenses, while pipeline progress remains in focus.
View source ↗
Earnings
Tue, Nov 3(in 4 weeks)
Consensus estimate $-0.34 per share
Typical surprise -2.0% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Aug 10$-0.37 vs $-0.32miss
- Wed, May 13$-0.32 vs $-0.31miss
- Thu, Mar 5$-0.29 vs $-0.31beat
- Tue, Nov 4$0.13 vs $0.01beat
- Tue, Aug 5$-0.35 vs $-0.35beat
- Mon, May 12$-0.36 vs $-0.34miss
Estimates and results for TNGX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by TNGX officers and directors.
- Bought
- —
- Sold
- $33.5m
0 trades
37 trades
- Newcomb Jessicasold
- Newcomb Jessicasold
- Newcomb Jessicasold
- Crystal Adamsold
- Crystal Adamsold
- Crystal Adamsold
- Crystal Adamsold
- Crystal Adamsold
63 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in TNGX.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.